NYSE
$145.11▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $358.40BShares out 24.700M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
23- 2d agoAfter-hours26.10.23 05:053/AOwnership#●●●
Merck & Co., Inc.
Merck & Co., Inc. executive David R. Maraldo has filed an amended Form 3/A to correct his statement of beneficial ownership of securities. This filing is an administrative update regarding insider holdings and does not involve any changes to the company's financial position or business operations.…more
$145.11+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15Pre-market26.10.15 22:2925-NSEOther
Merck & Co., Inc.
The New York Stock Exchange has confirmed the delisting and deregistration of Merck & Co., Inc.'s specified securities, effective October 26, 2026, following their redemption at maturity on October 15, 2026. Trading of the securities was suspended on the maturity date of October 15, 2026.…more
$145.11+0.00%vs prev closeView filingShare - 10.13Regular26.10.14 01:368-KKey event
Merck & Co., Inc.
Merck & Co., Inc. has appointed Paul J. Diaz to its Board of Directors, effective November 1, 2026. Mr. Diaz will serve on both the Audit Committee and the Research Committee, bringing the total number of board members to 14.…more
$145.11+0.00%vs prev closeView filingShare
22 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoRegular26.10.23 04:08Bullish#●●●#●●●
FDA Grants Traditional Approval for Keytruda Indication Expansion
The FDA has granted traditional approval for the expansion of Keytruda's indication for unresectable or metastatic solid tumors. This regulatory milestone strengthens the drug's market position and is expected to support continued revenue growth.…more
$145.11+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 2d agoRegular26.10.23 04:05
●●●●●●●● ●●●●● ●●●●●●
Merck and Moderna announced that their investigational mRNA cancer therapy significantly reduced the risk of recurrence or death in melanoma patients during a Phase 3 trial. The companies are now engaging with regulatory authorities based on these positive clinical data.…more
$145.11+0.00%vs prev closeShareBenzinga - 2d agoRegular26.10.23 03:47
●●●●●●●● ●●●●● ●●●●●●
Moderna stock fell over 25% following an alleged leak of Phase 3 clinical data for its personalized melanoma vaccine, which suggested lower efficacy than previous studies. The market reacted negatively to concerns that the vaccine may offer less benefit than initially anticipated.…more
$145.11+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report